|
|
|
| Efficacy of growth hormone in children with short stature complicated with benign thyroid nodules |
| ZHU Yanli1,2, TANG Aimei1, GU Qi1, TAN Juan1, LI Yue′e1, XU Yuanyuan3, WANG Jie3, TANG Yongquan3, ZHOU Wendi1,3 |
(1. Department of Pediatrics, Huai′an Clinical College of Xuzhou Medical University, Huai′an Jiangsu 223300; 2. Department of Pediatrics, Lianshui People′s Hospital of Kangda College Affiliated to Nanjing Medical University, Huai′an Jiangsu 223400; 3. Department of Pediatrics,the Affiliated Huai′an No.1 People′s Hospital of Nanjing Medical University， Huai′an Jiangsu 223300, China)
|
|
|
|
Abstract Objective： To observe the effect of growth hormone on children with short stature complicated with benign thyroid nodules. Methods： Forty-seven children with short stature complicated with benign thyroid nodules who received growth hormone treatment in the Department of Pediatrics, Huai′an Clinical College of Xuzhou Medical University from January 2021 to October 2022 were selected as the treatment group. Thirty short stature children whose parents refused to receive growth hormone treatment were randomly selected as the control group. The changes of height and thyroid function were observed at the first visit, the 6th month and the 12th month. Results： The height and growth rate were significantly increased and the height standard deviation scores (HtSDS) were improved after 6 and 12 months treatment with growth hormone, the levels of insulinlike growth factor-1 (IGF-1) were significantly higher than those in the controls (P<0.05). In the control group, the height at the 6th and 12th month of follow-up was higher than that at the first visit (P<0.05), but the increase was not as significant as that in the treatment group. Growth rate, HtSDS and IGF-1 levels had no significant changes before and after re-diagnosis. In the treatment group, the maximum cross-sectional diameter and grade of benign thyroid nodule had no significant change after treatment (P>0.05), and the level of FT4 had no significant difference before and after treatment, the levels of TSH and FT3 were in the normal range after treatment. Conclusion： Growth hormone therapy could effectively improve the height of short children with benign thyroid nodules, and produce no significant effect on benign thyroid nodules. It is recommended to use growth hormone therapy for such children.
|
|
Received: 07 November 2022
|
|
|
|
［1］杨丽萍, 宇根于, 谢宇飞. 重组人生长激素在儿童生长激素缺乏症和特发性矮小症治疗中的临床应用［J］. 中国药物与临床, 2021, 21(11): 1849-1851.
［2］辛颖. 儿童甲状腺结节的诊治［J］. 临床儿科杂志, 2013, 31(12): 1109-1112.
［3］巩纯秀, 王嘉丽. 儿童甲状腺结节的识别和处理［J］. 中华实用儿科临床杂志, 2019, 34(8): 565-570.
［4］国家儿童医学中心, 国家儿童肿瘤监测中心, 中华医学会小儿外科学分会, 等. 中国儿童甲状腺结节及分化型甲状腺癌专家共识［J］. 中华实用儿科临床杂志, 2020, 35(20): 1521-1530.
［5］中华医学会儿科学分会内分泌遗传代谢学组. 矮身材儿童诊治指南［J］. 中华儿科杂志, 2008, 46(6): 428-430.
［6］Francis GL, Waguespack SG, Bauer AJ, et al. Management guidelines for children with thyroid nodules and differentiated thyroid cancer［J］. Thyroid, 2015, 25(7): 716-759.
［7］中华医学会内分泌学会《中国甲状腺疾病诊治指南》编写组. 中国甲状腺疾病诊治指南——甲状腺结节［J］. 中华内科杂志, 2008, 47(10): 867-868.
［8］刘鸿丽, 张晶, 李风侠. rhGH治疗特发性矮身材患儿的疗效及对IGF1水平的影响［J］. 中国妇幼健康研究, 2021, 32(12): 1867-1870.
［9］郝坤, 郝磊. 甲状腺癌患者行甲状腺全切除术对血清iPTH、IGF1水平及预后的影响［J］. 国际检验医学杂志, 2021, 42(18): 2234-2236, 2240.
［10］李小勤, 崔凡, 钱增堃, 等. 2型糖尿病患者体内胰岛素样生长因子1与甲状腺结节的相关性研究［J］. 医学研究杂志, 2021, 50(2): 53-56.
［11］张玥熠, 杨青, 冯莉娟, 等. 胰岛素样生长因子1在中枢神经系统疾病发生发展中的作用及机制研究进展［J］. 山东医药, 2022, 62(2): 100-103.
［12］Meazza C, Elsedfy HH, Pagani S, et al. Metabolic parameters and adipokine profile in growth hormone deficient (GHD) children before and after 12month GH treatment［J］. Horm Metab Res, 2014, 46(3): 716-759.
［13］王仙花, 吕春雷, 孔原. 甲状腺功能亢进症患者生长激素胰岛素样生长因子1轴及抗氧化能力指标的研究［J］. 中国现代医学杂志, 2020, 30(9): 34-37.
［14］万乃君, 张田, 张金, 等. 长效重组人生长激素治疗儿童生长激素缺乏症的有效性及安全性研究［J］. 中国儿童保健杂志, 2021, 29(7): 755-758, 771.
［15］Grimberg A, DiVall SA, Polychronakos C, et al. Guidelines for growth hormone and insulinlike growth factorⅠ treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulinlike growth factorⅠ deficiency［J］. Horm Res Paediatr, 2016, 86(6): 361-397.
［16］Palmieri VV, Lonero A, Bocchini S, et al. Uniparental disomy and pretreatment IGF1 may predict elevated IGF1 levels in PraderWilli patients on GH treatment［J］. Growth Horm IGF Res, 2019(48/49): 9-15.
［17］王颖, 梁芙蓉. 矮身材儿童治疗前后甲状腺功能变化研究进展［J］. 中华实用儿科临床杂志, 2016, 31(20): 1595-1597.
［18］鄢力, 苟鹏, 唐芳, 等. 重组人生长激素对生长激素缺乏症患儿部分相关激素水平的影响［J］. 贵州医科大学学报, 2017, 42(5): 557-560, 565.
［19］黄诚花, 李林祖, 张明真, 等. 生长激素治疗矮小症患儿的效果及对甲状腺功能的影响［J］. 河南医学研究, 2018, 27(16): 2919-2921.
|
|
|
|
